Therefore, when treating cancers with a BH3 profiling pattern similar to parental and 5-FU-resistant HCT-15 cells, BCLXL-inhibitor treatment may be better after acquiring 5-FU resistance. This evidence concerns the gene BCL2L1 and cancer.